Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
08 June 2024 - 3:00AM
Oxurion Receives Transparency Notification from Atlas Special
Opportunities LLC
Oxurion Receives Transparency
Notification from Atlas Special Opportunities LLC
Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET -
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company
headquartered in Leuven, today announced that, pursuant to Belgian
Transparency legislation1 it has received a transparency
notification as follows:
Oxurion received a transparency notification on
June 7, 2024, from Atlas Special Opportunities, LLC indicating that
as of June 7, 2024, it held 1,785,024,954 shares of the then
outstanding 12,275,690,851 shares, and therefore crossed below the
threshold (15%) by virtue of the sale of voting securities. See
Annex 1.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in
developing next-generation standard of care ophthalmic therapies
for the treatment of retinal disease. Oxurion is based in Leuven,
Belgium. More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please contact:
|
Oxurion NVPascal GhosonChief Executive
OfficerPascal.ghoson@oxurion.com |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on
disclosure of major holdings.
ANNEX 1
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Oxurion NV (EU:OXUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
